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Background: 
Although a brachial plexus block can be used to provide anesthesia and analgesia for upper extremity surgery, 
its effects using MgSO4 on postoperative pain management have not been reported. The aim of this study was 
to evaluate brachial plexus block using MgSO4 on postoperative analgesia.
Methods:
Thirty-eight patients who were scheduled to undergo upper extremity surgery were randomly allocated into 
two gr oups: patients r eceiving axillary brachial plexus block w ith 0.2%  r opivacaine 20 ml and normal saline 
2 ml (group S) or 0.2% ropivacaine 20 ml and MgSO4 200 mg (group M). Before extubation, the blocks were 
done and patient controlled analgesia was started, and then, the patients were transported to a postanesthetic 
care unit. The postoperative visual analogue scale (VAS), opioid consumption, and side effects were recorded.
Results:
The two groups were similar regarding the demographic variables and the duration of the surgery. No 
differences in VAS scores were observed between the two groups. There was no statistically significant difference 
in opioid consumption between the two groups. Nausea was observed in three patients for each group.
Conclusions:
Axillary brachial plexus block using MgSO4 did not reduce the level of postoperative pain and opioid 
consumption.  (Korean  J  Pain  2011;  24:  158-163)
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INTRODUCTION
　　Patients undergoing orthopedic surgery for upper ex-
tremity injuries often report postoperative pain that is in-
tense and difficult to control. The pain itself is not only 
associated with a number of complications that can devel-
op in patients but can also lead to an unintended long- 
term stay in the hospital after surgery [1].  Various  ap-
proaches have thus been adopted to help alleviate post-
operative pain, with the majority of them using high doses 
of opioids. Opioids, however, have side effects such as se-
vere nausea and vomiting.
　　Nerve blocks, mostly using topical anesthetics, reduce 
the  side  effects  of  anesthesia  by  using  large  doses  of 
opioids, which can control postoperative pain effectively. 
The brachial plexus block (BPB) in particular is a widely 
used option in upper extremity surgeries. During a BPB, 
various drugs are used in combination with local anes-
thetics to help reduce the anesthetics’ time to onset of ef-
fect, to prolong the duration of action, and to increase the 
chance of successful blockade. Toward these ends, a num-
ber of studies have been done, with varying results [2-11].
　　The magnesium helps to regulate the amount of cal-
cium inside the cells and is known to be able to control 
for pain. For example, magnesium sulfate (MgSO4), when 
i n j e c t e d  i n t r a v e n o u s l y ,  h e l p s  r e d u c e  t h e  c o n s u m p t i o n  o f 
anesthetics  during  surgeries;  in  addition,  when  ad-
ministered through epidural injection, it helps to decrease 
the amount of opioids needed postoperatively [12]. Despite 
its known benefits for pain control, magnesium has never 
been studied extensively for its effects as an adjuvant to 
aesthetics during BPBs, much less for its synergistic ef-
fects during BPBs when used in combination with ropiva-
caine, a local anesthetic used widely in recent years.
　　In this study, we did axillary brachial plexus blocks 
(A B PBs), a po p u l ar n erv e b l oc k tec hn i qu e, as a w a y to 
c o n t r o l  p o s t o p e r a t i v e  p a i n  i n  p a t i e n t s  w h o  u n d e r w e n t  a 
surgery in their brachial regions. We examined the effects 
o f  a  r o p i v a c a i n e - m a g n e s i u m  r e g i m e n  u s e d  d u r i n g  t h e  
ABPBs on the patients’ postoperative pain, on the con-
sumption of opioids, and on reported side effects.
MATERIALS  AND  METHODS
　　We enrolled 38 male and female patients, ages 15 to 
6 5, w h o w er e sc h ed u l ed to un d er g o an u p per e xt r em i t y 
surgery and who met the requirements of the American 
Society of Anesthesiologists (ASA) physical status classi-
fication system’s Class 1 or Class 2. The exclusion criteria 
were a history of lung disease, obesity (body mass index 
＞ 30 kg/m
2), a history of chronic pain or psychiatric dis-
order, drug or alcohol abuse, and hypersensitivity to local 
anesthetics. The prospective study design was approved by 
the institutional review board (IRB) at this hospital.  The 
purpose and methods of the study were explained to the 
participating patients; their written consent was collected 
prior to the study.
　　The patients were randomly assigned to either group 
S (ropivacaine-saline injected group) or group M (ropiva-
caine-magnesium injected group). All patients were trans-
ported to the operating room without being administered 
a preoperative anesthetic or analgesic. Their ECG, blood 
pressure, and oxygen saturation level were monitored by 
means of an ECG machine, a noninvasive blood pressure 
(NIBP) monitor, and a pulse oximeter.  To  induce  general 
anesthesia in the patients, 2% lidocaine (1 mg/kg) and 1% 
propofol (2-2.5 mg/kg) were injected intravenously. Upon 
confirming the induced unconsciousness in the patients, 
rocuronium (0.6 mg/kg), a nondepolarizing muscle relax-
ant, was injected intravenously; after 90 seconds, endo-
tracheal intubation was done; the positioning of the tube 
was checked. O2 and N2O were each maintained at 1 L/m, 
while desflurane was maintained at 4-6 Vol% depending on 
the response of the patient’s autonomic nervous system. 
If the systolic blood pressure of the patient increased more 
than 30% from his or her baseline reading that was taken 
in their hospital room prior to the anesthesia, 0.5 mg of 
nicardipine was injected intravenously.
　　Upon completion of the upper extremity surgery, an 
ABPB was done. A band was applied on the distal site of 
the operated area; the arm upon which the operation was 
performed was abducted to 100 degrees supine and was 
flexed at the elbow joint to 90 degrees. The axillary artery 
was palpated at a site situated in the armpit, about 1 cm 
off from the lateral edges of the pectoralis major; the site 
was marked for injection. Betadine (topical antiseptic) was 
applied to the site; a 23-gauge scalp vein needle, con-
nected to the syringe containing the drugs, was advanced 
into the skin slowly. As the needle continued to infiltrate 
into the skin, the site of blood regurgitation was located; 
and the site where the needle was further advanced and 
the site where the needle was retrieved were each marked. 160 Korean J Pain Vol. 24, No. 3, 2011
Table 1. Patients’ Demographic Characteristics and Surgical 
Characteristics
Group S (n = 20)Group M (n = 18)
Age (yr)
Gender (M/F)
Height (cm)
Weight (kg)
Duration of surgery (min)
49.6 ± 15.4
5/15
160.9 ± 8.4
 64.3 ± 8.6
75.5 ± 36.3
  48.2 ± 13.4
 10/8
163.6 ± 7.7
  65.7 ± 11.3
  77.8 ± 32.9
Data are expressed as mean ± SD or number of patients. Group 
S: BPB with 0.2% ropivacaine 20 ml + normal saline 2 ml. Group 
M: BPB with 0.2% ropivacaine 20 ml + MgSO4 200 mg. There were
no significant differences between the two groups. BPB: brachial 
plexus block.
The surgical assistant did the block by injecting the sites 
with 20 ml of 0.2% ropivacaine (Ropiva Injection, Hanlim 
Pharm Co., Ltd.) combined with normal saline solution if 
the patient was in group S, and a mixture of 0.2% ropiva-
caine (20 ml) and 200 mg of MgSO4 (Magnesium Daihan 
Injection, Daihan Pharm., Co., Ltd.) if the patient was in 
group M. Both drug regimens were prepared prior to the 
block. Upon the completion of the ABPB, the endotracheal 
tube was removed; a patient-controlled analgesia (PCA) 
device was hooked up to the patient’s intravenous line; the 
patient was transported to his or her recovery room. The 
drug mixture (100 ml) used for the PCA device contained 
1,000  μg of f en tan y l (B C F en tan y l Cit r ate Injecti on, BC 
W o r l d  P h a r m , C o .,  L t d .) , 0 . 3 m g o f r a m os e t r o n  (N a s ea 
Injection, Astellas Pharma Korea, Inc.), and normal saline 
solution. In all patients, the per-injection amount of fen-
tanyl  was  0.2  μg/kg; the lockout interval was set at 5 
minutes.
　　Prior to the surgery, the patients were educated on 
how to use the PCA device and how to rate on the visual 
analogue scale (VAS), i.e., a line along which patients rate 
the severity of their perceived pain by marking a number 
(0 to 10) that best represents the pain.  Before inducing 
anesthesia in the patients, baseline VAS scores were col-
lected from the patients and their sensory and motor re-
sponsiveness  were  tested.  For  sensory  responsiveness 
testing, the dermatomere of the area covering the pa-
tient’s C6 through C8 was pinpricked (e.g., the radial, ul-
nar, and median nerves); in addition, both of the arms 
were  stimulated  using  the  same  amount  of  pressure  in 
each arm to compare their responsiveness. Three rating 
options were offered: ‘1’ represents the loss of all sensory 
responsiveness, ‘2’ the loss of pain sensations, and ‘3’ the 
maintenance of full sensory responsiveness. For motor re-
sponsiveness testing, we checked the dorsiflexion, adduc-
tion, and abduction of the patients’ fingers. The patients 
were offered three rating options: ‘ 1’ indicates no motor 
responsiveness; ‘2’ indicates weak motor responsiveness; 
and ‘3’ indicates maximum motor responsiveness.
　　In the recovery room, an anesthesiologist, unaware of 
the study design (i.e., patient assignment to each of the 
two treatment groups), collected the patients’ V A S pain 
score,  tested  their  motor  and  sensory  responsiveness, 
checked the amount of fentanyl administered through the 
PCA device postoperatively, measured their blood pressure 
and heart rate, and asked if the patients’ experienced any 
adverse events, such as headache, nausea, vomiting, and 
dizziness.  Data on each of these categories were taken 
immediately after the surgery, at 30 minutes after the 
surgery, and at 1 hour after the surgery. In addition, the 
data were collected at 2 hours, 3 hours, 6 hours, 12 hours, 
and 24 hours afterwards by visiting the patients in their 
room. A successful ABPB was defined as the patients’ rat-
ing their sensory responsiveness as either ‘1’ or ‘2’ on the 
VAS scale. If the patient reported adverse events such as 
nausea or vomiting, 4 mg of ondansetron (Ondant Injec-
tion, Hanmi Pharm Co., Ltd.) was injected intravenously.
　　All statistical data analyses were done with SPSS ver-
sion 12.0 software (SPSS, Chicago, IL, USA). Comparison 
between group S and group M in terms of gender, adverse 
events, and motor and sensory responsiveness was done 
by means of the chi-squared test.  Comparison between 
the groups’ age, stature, weight, duration of surgery, VAS 
pain score, blood pressure, heart rate, and fentanyl con-
sumption was done with Student's t-test. Analytical results 
were considered statistically significant if the P value was 
less than 0.05.
RESULTS
　　There were no significant differences in the patients’ 
gender, age, height, weight, duration of surgery, or type 
of surgery between group S and group M (Tables 1 and 2). 
In terms of time-specific VAS pain scores collected post-
operatively  (Fig.  1),  fentanyl  consumption  (Table  3),  and 
changes in blood pressure and heart rate, no significant 
differences were observed between the groups. The pin-
prick test done on the patients’ dermatomere 30 minutes IG Choi, et al / Effects of Postoperative Brachial Plexus Block 161
Table 2. Surgical Types
Surgical types
Group S
(n = 20)
Group M 
(n = 18)
 Open reduction & internal fixation
 Closed reduction & pinning
 Tenorrhaphy
18
 1
 1
16
 1
 1
Group S: BPB with 0.2% ropivacaine 20 ml + normal saline 2 ml. 
Group M:  BPB with 0.2% ropivacaine 20 ml + MgSO4 200 mg. 
There were no significant differences between the two groups. 
BPB:  brachial plexus block.
Table 3. Postop Opioid Consumption
Group S (n = 20) Group M (n = 18)
 0 h
0.5 h
 1 h
 2 h
 3 h
 6 h
12 h
24 h
0
 1.6 ± 1.3
 3.9 ± 2.3
 7.5 ± 4.2
10.6 ± 6.8
 17.1 ± 11.2
 27.7 ± 16.1
 37.4 ± 24.0
0
 1.7 ± 1.7
 4.0 ± 3.1
 9.1 ± 6.7
 12.2 ± 10.1
 17.4 ± 14.3
 26.2 ± 21.2
 28.6 ± 21.0
Data are expressed as mean ± SD. Group S: BPB with 0.2% ropi-
vacaine 20 ml + normal saline 2 ml. Group M: BPB with 0.2% ropi-
vacaine 20 ml + MgSO4 200 mg. There were no significant differ-
ences between the two groups.  BPB:  brachial plexus block.
Table 4. Side Effects
S i d e  e f f e c t s Gr o u p  S  ( n  = 2 0 ) Gr o u p  M ( n  = 1 8 )
 Headache
 Nausea
 Vomiting
 Dizziness
0
3
1
2
1
3
0
0
Group S: BPB with 0.2% ropivacaine 20 ml + normal saline 2 ml. 
Group M:  BPB with 0.2% ropivacaine 20 ml + MgSO4 200 mg. 
There were no significant differences between the two groups. 
BPB:  brachial plexus block. Fig. 1. Postoperative pain scores on a visual analogue scale
(VAS). Brachial plexus block was performed using 20 ml of
0.2% ropivacaine, added normal saline 2 ml in group S, 
MgSO4 200 mg in group M. There were no significant 
difference between the two groups. Data are expressed as
mean ± SD.
after the surgery found that 80% of group S marked either 
‘1’ (loss of all sensory responsiveness) or ‘2’ (loss of pain 
sensations)  on  the  VAS  scale,  while  the  corresponding 
number in group M was 72%. The same test done 12 hours 
after the surgery, however, showed that all patients re-
covered their sensory responsiveness. Regarding the pa-
tients’ motor responsiveness, the results of the pressure 
test done 30 minutes after the surgery showed that 68% 
of group S marked either ‘1’ (no motor responsiveness) or 
‘2’ (weak motor responsiveness) on the V AS scale, while 
the corresponding figure in group M was 60%. The same 
test done 12 hours after the surgery, however, showed that 
all patients recovered their motor responsiveness. Nausea 
was  reported  in  3  patients  in  group  S  and  group  M, 
respectively. Vomiting was observed in 1 patient in group 
S; the inter-group difference, however, was not significant 
(Table 4).
DISCUSSION
　　P r e vi o u s s t u d i e s h a v e  r e p o r t ed  t h e u se  o f a d j u v a n t 
drugs during BPBs. Kim [6] and Singelyn et al. [13] ob-
served  that  clonidine  (α2-receptor  agonist)  used  during 
BPB prolonged the duration of the anesthetic action and 
pain control; they noted the benefits were the topical ef-
fects of the clonidine, not general ones. Other drugs used 
during BPBs included tramadol, an opioid, and an α2 re-
ceptor agonist. When used in combination with local anes-
thetics during a BPB, tramadol helped prolong the blocking 
of sensory and motor nerve transmissions to the brain [14].
　　Other studies have reported the use of narcotic drugs 
such as fentanyl and alfentanil, administered in combination 
with local anesthetics during BPBs. The drugs were found 
to help block sensory and motor nerve transmissions [2,5].162 Korean J Pain Vol. 24, No. 3, 2011
　　Magnesium,  a  cation  existing  inside  the  cell  whose 
quantities are second only to potassium, plays a crucial 
role in activating enzymes in the cardiovascular system. 
I n  a d d i t i o n ,  m a g n e s i u m  a c t s  a s  a  p h y s i o l o g i c a l  c a l c i u m 
antagonist. It is used to treat arrhythmia, myocardial or 
nerve ischemia, and gestational toxicosis, and to inhibit 
uterine  contraction  [15,16].  More  recently,  magnesium’s 
effects of N-methyl-D-aspartate (NMDA) receptor antag-
onism  and  sympathetic  blocking  have  been  noted,  and 
magnesium is now used to help reduce the consumption 
o f  a n e s t h e t i c s  a n d  p a i n  m e d i c a t i o n s  [ 1 2 , 1 7 ] .  Magnesium 
blocks the effects of excitatory amino acids (e.g., gluta-
m a t e ,  a s p a r t a t e )  o n  N M D A  r e c e p t o r s  a n d  c o n t r i b u t e  t o 
central sensitization [18,19].
　　Studies on the pain control effects of magnesium have 
shown conflicting results. Lee et al. [20] reported that the 
preoperative intravenous injection of magnesium was ef-
fective in controlling postoperative pain. On the contrary, 
Ko et al. [21] reported that the same approach was not 
effective.
　　There are only a small number of studies that have 
used MgSO4 during BPBs. Gunduz et al. [22] used prilo-
caine, a local anesthetic, during a BPB and observed that 
the drug, when used in combination with magnesium, pro-
longed the duration of the sensory and motor nerve block 
without causing adverse events. Goyal et al. [23] reported 
that the injection of MgSO4 into the axillary sheath, with-
o u t  a d d i n g  a  t o p i c a l  a n e s t h e t i c ,  r e d u c e d  p o s t o p e r a t i v e  
pain.  In this stud y, w e used r opiv acaine in com bination 
with magnesium during ABPBs.  The use of magnesium, 
however, did not result in significant differences in post-
operative VAS pain scores or fentanyl consumption be-
tween the two groups. Differences between this study and 
the study by Gunduz et al. [22] were the use of ropivacaine 
and the adoption of a different dose (20 ml) during the 
block. We used ropivacaine because it has a higher thresh-
old value than lidocaine and offers a longer duration of ac-
tion, and because it has less cardiovascular toxicity than 
bupivacaine. However, we note the combination of prilo-
caine and magnesium (the study by Gunduz et al.) and the 
c o m b i n a t i o n  o f  r o p i v a c a i n e  a n d  m a g n e s i u m  ( t h i s  s t u d y )  
might  have  resulted  in  different  pain  control  effects  of 
magnesium. As for our use of a smaller dose, we used 20 
ml of ropivacaine because our aim was at reducing post-
operative  pain  resulting  from  general  anesthesia  during 
ABPBs and not to provide an adjuvant drug for the anes-
thesia during a block, which was the case in the study by 
Gunduz et al. [22]. Another reason why we considered our 
selected  dose  to  be  sufficient  enough  to  control  post-
operative pain was due to the study by Goyal et al. [23] 
that used the same dose (i.e., 20 ml) of magnesium with-
out any other anesthetics during a BPB in order to control 
postoperative pain.
　　In this study, we did not use a control group, whereas 
some of the previous studies have used a control group 
that  was  administered  non-steroidal  anti-inflammatory 
d r u g s  ( N S A I D s )  v i a  i n t r a v e n o u s  i n j e c t i o n .   Technically 
speaking, however, a group injected with NSAIDs does not 
constitute a control group due to the anti-inflammatory 
effects of the drugs. In addition, we suspect that the use 
o f  a  c o n t r o l  g r o u p  i n j e c t e d  w i t h  n o r m a l  s a l i n e  s o l u t i o n 
might even lead to distinct effects of its own; moreover, 
the patients might experience pain or discomfort when in-
jected with 20 ml of normal saline solution. Thus, we ex-
cluded the use of control group on ethical grounds and as 
a  result  do  not  know  what  kinds  of  effects  a  ropiva-
caine-only regimen would have had on postoperative pain 
control had it been used during ABPBs. Note that with the 
generally same category of upper extremity surgery, pa-
tients undergoing one may feel different postoperative pain 
depending on the site and type of the surgery. Although 
we specified what was involved in the surgery (e.g., open 
reduction, closed reduction, tenorrhaphy), we see the need 
to further specify upper extremity surgery according to its 
site and type. In addition, we recommend a larger sample 
size  for  future  studies,  considering  ours  was  relatively 
small.
　　In this study, no serious adverse events were reported 
in either group. There were no significant differences be-
tween the groups in terms of occurrence of adverse events 
such as headaches, nausea, vomiting, and dizziness. We 
attribute the finding to the fact that both groups under-
went general anesthesia; however, we note the fact that 
only one dose of magnesium was used. Future studies may 
need to investigate the possibilities of adverse events re-
sulting from different doses of magnesium.
　　In summary, the postoperative pain control effects of 
0.2% ropivacaine (20 ml) combined with magnesium used 
during ABPBs were compared with the effects of 0.2% ro-
pivacaine (20 ml) combined with normal saline solution. 
The results show that there were no statistically significant 
differences between the groups in terms of their VAS pain IG Choi, et al / Effects of Postoperative Brachial Plexus Block 163
s c o r e ,  s e n s o r y  a n d  m o t o r  r e s p o n s i v e n e s s ,  a n d  f e n t a n y l  
consumption.
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